Project COMET: Massed Prolonged Exposure for PTSD and SUD
The goal of this clinical trial is to learn if Massed Prolonged Exposure Therapy (M-PE) can improve PTSD symptoms and reduce substance use in adults receiving intensive outpatient (IOP) treatment for substance use disorder (SUD). The main questions it aims to answer are: * Does M-PE reduce PTSD symptoms more effectivel
| Condition(s) | Posttraumatic Stress Disorder (PTSD), Substance Use Disorders (SUD), Comorbidity, Trauma and Stressor Related Disorders |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The goal of this clinical trial is to learn if Massed Prolonged Exposure Therapy (M-PE) can improve PTSD symptoms and reduce substance use in adults receiving intensive outpatient (IOP) treatment for substance use disorder (SUD). The main questions it aims to answer are: * Does M-PE reduce PTSD symptoms more effectively than trauma treatment as usual (TAU)? * Does M-PE reduce the number of days participants use substances? * How do patient-centered outcomes (such as depression, suicidal thoughts, and quality of life) differ between M-PE and trauma TAU? * Researchers will compare M-PE to treatment as usual to see if M-PE leads to better mental health and substance use outcomes and lower dropout rates. Participants will: * Attend multiple therapy sessions per week (M-PE) or receive usual car |
| Who can participate | Inclusion Criteria: * Age 18+ * Enrolled in SUD treatment at Gateway Community Services * Meet DSM-5 criteria for a SUD (Tobacco Use Disorder alone not sufficient for inclusion) * Meet DSM-5 criteria for PTSD * Able to give informed consent Exclusion Criteria: * severe cognitive impairment * current suicidal or homicidal intent requiring immediate treatment * current unstable psychotic or manic symptoms not attributable to SUD |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Rutgers, The State University of New Jersey |
| Locations | Jacksonville, Florida, United States |
| Start date | 2025-09-02 |
| NCT ID | NCT06968832 |
| Official listing | https://clinicaltrials.gov/study/NCT06968832 |